Walleye Capital’s Pyxis Oncology PYXS Stock Holding History

Walleye Capital’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-119,561	Closed	-$265K	–	5008
2025 Q3	$265K	Buy	+119,561	New	+$172K	﹤0.01%	3116
2022 Q1	–	Sell	-15,933	Closed	-$175K	–	2534
2021 Q4	$175K	Buy	+15,933	New	+$182K	0.01%	1520

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's PYXS Position: Q4 2025 in Review

Walleye Capital sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 119,561 shares — an estimated $265K sold.

Walleye Capital first reported a position in PYXS in Q4 2021 and held it in 2 quarters. The position peaked at $265K in Q3 2025. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

Walleye Capital reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 119,561 Pyxis Oncology shares in Q4 2025, an estimated $265K.
Walleye Capital first reported a position in Pyxis Oncology in Q4 2021 and held it in 2 quarters.
Walleye Capital's Pyxis Oncology position peaked at $265K in Q3 2025.
79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.